Hyperbaric Oxygen Therapy : A new Evolving Future Perspective for Management of Mucormycosis and COVID 19 in Children in Developing Countries

Authors

  • Mahaveer Lakra Department of Paediatrics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (DMIMS), Sawangi Meghe, Wardha, Maharashtra, India
  • Amar Taksande Department of Paediatrics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (DMIMS), Sawangi Meghe, Wardha, Maharashtra, India
  • Bhavana Lakhkar Department of Neonatology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (DMIMS), Sawangi Meghe, Wardha, Maharashtra, India
  • Sachin Damke Department of Paediatrics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (DMIMS), Sawangi Meghe, Wardha, Maharashtra, India
  • Ashwini Lakra Senior Resident, Datta Meghe Medical College and SMHRC, Wanadongri, Nagpur, Maharashtra, India

DOI:

https://doi.org/10.3126/jnps.v42i1.42443

Keywords:

COVID 19, Hyperbaric oxygen, Mucormycosis, Oxygen tank, Tissue hypoxia

Abstract

The SARS COVID-19 virus has arisen as a major hazard to mankind, posing harm to the whole world population. During the second COVID wave, mucormycosis has emerged as one of the deadliest and most devastating illnesses. Mucormycosis is strongly associated with diabetes, prolonged use of steroids, prolonged hospitalisation and immunocompromised states. Children have also been affected by this badly. Hyperbaric oxygen therapy is a non-invasive, cost-effective and painless therapy where 100% oxygen is given to patients under high atmospheric pressure in small tents or chambers. It helps in tissue regeneration and angiogenesis. Hyperbaric oxygen has proved to be effective in the treatment of oculo-rhino-cerebral mucormycosis. Various studies have proved its role in the management of mucormycosis and acute respiratory distress syndrome associated with COVID-19 infection. The advantages of hyperbaric oxygen are same in children as in adults with minimum side effects. Hyperbaric oxygen therapy can be one of the good adjunctive therapies in the management of mucormycosis. It is found to be safe in the treatment of COVID-19 infection, but data is still limited on its use and further studies are needed. This article is all about its use, its efficacy, and future perspectives in the management of mucormycosis and COVID-19 in view of the arrival of the third COVID wave in developing countries like India.

Downloads

Download data is not yet available.
Abstract
180
PDF
136

Downloads

Published

2022-11-27

How to Cite

Lakra, M., Taksande, A., Lakhkar, B., Damke, S., & Lakra, A. (2022). Hyperbaric Oxygen Therapy : A new Evolving Future Perspective for Management of Mucormycosis and COVID 19 in Children in Developing Countries. Journal of Nepal Paediatric Society, 42(1), 1–7. https://doi.org/10.3126/jnps.v42i1.42443

Issue

Vol. 42 No. 1 (2022)

Section

Review Article

License

Copyright (c) 2022 Mahaveer Lakra, Amar Taksande, Bhavana Lakhkar, Sachin Damke, Ashwini Lakra

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).